Cancer is bad enough in one spot, but the disease gets especially dangerous once it starts migrating throughout the body. Finding ways to stop this process, known as metastasis, is a key way to improve survival rates for patients. Now researchers have found that primary tumors have their own mechanism for slowing the growth of secondary cancers, which...
Category: <span>Cancer</span>
Post
Protein modifications pointing to cancer
Cells use different signals to react to stress and to inform other body cells. Triggers are, for example, cancer or inflammatory diseases. A central signaling pathway of stress response is the modification of proteins called ADP-ribosylation. Small molecules (ADP ribose) are added to precisely defined protein sites to control protein function. IMAGE: THE ENZYME ARTC1 (RED)...
Post
Study provides new insights for ways to use cell metabolism to treat cancer
UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER CINCINNATI–Researchers at the University of Cincinnati (UC) College of Medicine have discovered that cell metabolism plays an important role in the ability of cells to start a survival program called autophagy, an unwanted side effect of some anti-cancer drugs that helps some tumor cells dodge treatment and eventually regrow into...
Post
Researchers reveal cause of aggressive skin cancer in patients with butterfly syndrome
The insights could open the door to a more effective treatment approach for patients with rare disorder THOMAS JEFFERSON UNIVERSITY PHILADELPHIA) – Patients with a rare skin disease, commonly called Butterfly Syndrome, that causes chronic blistering and extensive scarring also develop an aggressive and fatal form of cancer early in life. Now an international team...
Post
Combination approach shows promise for beating advanced melanoma
In UCLA-led study, new treatment is more effective in people receiving immunotherapy for the first time UNIVERSITY OF CALIFORNIA – LOS ANGELES HEALTH SCIENCES A UCLA-led study has found that a treatment that uses a bacteria-like agent in combination with an immunotherapy drug could help some people with advanced melanoma, an aggressive form of skin...
Post
Additional inhibitor can help anti-VEGF therapy overcome resistance in deadly brain cancer
Penn study identifies target, shows proof-of-concept in mice UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE PHILADELPHIA – Adding another inhibitor to therapies that cut off a tumor’s access to blood vessels could be the key to helping those therapies overcome resistance in glioblastoma, a deadly form of brain cancer. Drugs that target the vascular endothelial growth...
Post
APOBEC-Linked Mutational Signatures Drive Skin Cancer in Recessive Dystrophic Epidermolysis Bullosa
NEW YORK (GenomeWeb) – Mutational signatures linked to the APOBEC family drive the development of early-onset squamous cell carcinomas of the skin among individuals with a rare genetic disorder condition. Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic disorder caused by COL7A1 mutations that lead to skin fragility, tissue damage, and inflammation. Wounds that...
Post
Research team develops predictor for immunotherapy response in melanoma
In a new study, researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a novel type of immunotherapy. The predictor was developed by Noam Auslander, Ph.D., with other researchers in the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), part of the...
Post
Overlooked molecule might be key to how well cancer-fighting CAR-T cells work
Amostly overlooked component of CAR-T cells has a surprisingly strong effect on the cancer-fighting cells’ behavior, scientists reported on Tuesday, including in ways that might affect their safety and efficacy. The component is called the co-stimulatory domain, and the two CAR-T therapies approved last year to treat forms of leukemia and lymphoma — Yescarta and...
Post
Combination immunotherapy shrinks melanoma brain metastases
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the New England Journal of Medicine led by an investigator at The University of Texas MD Anderson Cancer Center. Hussein Tawbi, M.D., Ph.D. Credit: MD Anderson Cancer Center Of 94 patients in the single-arm study combining...